Methods: Twenty-three melanoma surgical biopsies (SBx) with an IPOX stain for PD-L1 clone 28-8, and a corresponding cytological specimen from the same patient, adequate for PD-L1 evaluation, were selected. Cell-transfer cell blocks (CBs) and conventional CBs were used to perform PD-L1 testing. Tumour proportion scores (TPS) were generated and the results were correlated with the corresponding SBx.
patients most likely to benefit from checkpoint inhibitor therapy, select patients at risk for adverse events, and monitor treatment response. While early studies in melanoma failed to show an association between PD-L1 expression and clinical outcomes, the phase III CheckMate 067 study, where nivolumab singly or combined with ipilimumab had longer progression-free survival (PFS) than ipilimumab alone, showed that PD-L1 negative tumours in patients given nivolumab and ipilimumab combination therapy compared to nivolumab alone had longer PFS. 5 PD-L1 immunoperoxidase (IPOX) 28-8 pharmDx has become an FDA approved complementary diagnostic test in melanoma patients. 6 The lack of a standardised cut-off value for PD-L1 positivity in melanoma specimens contributes to the difficulty in studying these cases. In the phase III CheckMate 067 study, PD-L1 expression was defined as at least 5% of tumour cells expressing PD-L1 28-8 in formalin-fixed paraffin embedded (FFPE) histological sections containing at least 100 tumour cells. 5 Using a positive cut-off of 5% for the Dako antibody 28-8, one study noted that there was a higher numerical objective response rate, longer PFS and longer overall survival seen in PD-L1-positive patients with melanoma. 7, 8 Another study looking at melanoma using a 1% cut-off for PD-L1 positivity
showed that PD-L1 expression was associated with improved objective response rate and PFS. 9 Immunostaining for PD-L1 clone 28-8 has primarily been validated in histological material using FFPE sections. However, histological material may not always be available or may be exhausted after use for other ancillary studies and cytological material may be the only tissue available for the evaluation of PD-L1 expression.
Studies looking at PD-L1 expression in cytological material are limited and most of the current literature in non-small cell lung carcinoma patients has shown high concordance of PD-L1 expression between cytological and histological FFPE tissue. [10] [11] [12] [13] However, an FFPE cell block material may not be always available for PD-L1 evaluation. Cell-transfer cell block (CTCB) can be utilised when there is no cell block (CB) or the CB material lacks adequate tumour cells for the evaluation of PD-L1 expression. Cell-transfer technique can be performed on direct smear slides and fixed in formalin to produce a CB as a surrogate for FFPE tissue. 14 Additional IPOX stains can then be performed on these CTCB specimens; good correlation with surgical FFPE sections has been reported. [14] [15] [16] In this study, we evaluate the PD-L1 28-8 IPOX stain in cytological FFPE specimen preparations including conventional CBs and CTCBs and compare these results to histological tissue from the same patient. To the best of our knowledge, this is the first study examining PD-L1 expression in various cytological tissues exclusively in melanoma patients.
| MATERIALS AND METHODS

| Case selection
Following approval from the Institutional Review Board a retrospective search was performed using the electronic medical record at remove the hardened Mount-Quick media containing the DS material and then placed in 10-30 mL of xylene for 10 minutes, until media dissolved. The specimen was centrifuged at 600 g for 10 minutes, and the supernatant was removed. 10 mL of fresh xylene was added for 5 minutes, and the specimen was centrifuged again at 600 g for 10 minutes followed by a wash in 100% ethanol. The resulting cell pellet was wrapped in filter paper and placed in a 10% formalin container for tissue processing. Haematoxylin and eosin staining was performed on the CB and CTCB sections. were re-reviewed and a consensus opinion was arrived at by the two cytopathologists.
| IPOX
| Study design
Cellular material was scored to include partial/complete membranous staining of tumour cells and placed into groups of less than 1%, ≥1%
and ≥5% TPS, regardless of staining intensity. Comparison of cytology material to the gold standard for PD-L1 TPS, surgical specimens, was performed using cut-offs of ≥1% and ≥5%. Positive percent agreement (PPA), negative percent agreement (NPA) and overall agreement (OA) were calculated by comparing PD-L1 expression to the corresponding surgical specimens.
3 | RESULTS ison, of the nine conventional CB cases evaluated, 77.8% (7/9) had ≥1% PD-L1 TPS, while 33.3% (3/9) had ≥5% PD-L1 staining (Table 2) . However, only 43.5% (10/23) of CTCB cases had ≥1%
| Case features
PD-L1 TPS, while 30.4% (7/23) had ≥5% PD-L1 immunoreactivity (Table 2) . CB compared to SBx had an OA of 88.9% (8/9), a PPA of 87.5%
(7/8), and an NPA of 100% (1/1) at a ≥1% cut-off and an OA of 55.6% (5/9), a PPA 42.9% (3/7) and NPA of 100% (2/2) at a ≥5% cut-off (Table 4 , Figs 1) . The single discordant case in the ≥1% cutoff group was a case that had a SBx TPS of 1% and a CB TPS of 0%. The four discordant cases at the ≥5% cut-off value included cases with a CB TPS of 1% (n = 4) and a SBx TPS of 5% (n = 2), 5%-10% (n = 1), and 10% (n = 1, (Table 5) . Studies looking at PD-L1 expression in melanoma have
shown that different antibody clones often perform similarly. 20, 21 Variation noted between assays is more likely due to intratumoural heterogeneity, rather than differences in antibody staining characteristics. 21 In general, the variation between assays used to assess PD-L1 IPOX staining, including differences in antibody, test conditions and scoring methods, has presented a challenge in analysing its use as a biomarker. assessment. 23, 24 In addition, in cases where serial sampling is needed, as PD-L1 expression has been shown to change after chemotherapy treatment, it may be easier to perform cytology aspirations. [25] [26] [27] Currently, the literature evaluating PD-L1 expression using cytological material is limited with most studies being done in non-small cell lung carcinoma patients. Skov et al examined 86 paired cytological and histological samples of lung malignancies stained with PD-L1 28-8 pharmDx and 22C3 pharmDx and found a high level of overall agreement of 85% to 94% and 87% to 95%, respectively, using a 1%
and 5% cut-off. 12 In general, it has been shown that EBUS-FNA specimens collected from the lung are often adequate for PD-L1 testing. 10, 11, 13 Indeed, some studies have found that cytological preparations may perform better than traditional histology along with good correlation with surgical material, with higher cell numbers and less crush artefact. This might due to the fact that aspiration IPOX expression in cytological preparations of melanoma are lacking and, to our knowledge, no correlative studies have been published thus far.
In our study, we show using a ≥1% cut-off there is good cor- 
